Crystalys_Tx

Transforming care for people living with gout.

[Crystalys_Tx @Crystalys_Tx]

Crystalys was recently featured in @GENbio, where @AlexWestchester highlighted our advancing clinical development program for dotinurad, including the Phase 2 AMETHYST study and ongoing Phase 3 RUBY and TOPAZ trials in #gout.

Read more: https://t.co/olPcARBK7f

[Crystalys_Tx @Crystalys_Tx]

Crystalys is looking forward to engaging with the #rheumatology and investment community at two upcoming events in June. We'll be sharing updates on our clinical progress and our efforts to advance new treatment options for patients living with #gout. https://t.co/qZMrLoO2Hm

[Crystalys_Tx @Crystalys_Tx]

Crystalys has dosed the first patients in our new Phase 2 AMETHYST study evaluating dotinurad in people with #gout who are intolerant to xanthine oxidase inhibitors or have failed uricase treatment.

For more details: https://t.co/TcP6zbcagA

[Crystalys_Tx @Crystalys_Tx]

Today on #GoutAwarenessDay, we recognize the millions of people living with a disease that is widely misunderstood despite being the most common form of inflammatory arthritis. We are committed to helping improve outcomes for patients living with #gout. https://t.co/57CUAZJwah

[Crystalys_Tx @Crystalys_Tx]

More than 12M Americans live with #gout, the most common form of inflammatory arthritis, and many lack options beyond first-line therapy. Crystalys is advancing dotinurad to help close the gap. #ArthritisAwarenessMonth

Learn more about our work: https://t.co/GknQLl2fP0

[Crystalys_Tx @Crystalys_Tx]

CEO James Mackay, Ph.D., recently joined Danny Levine on The Bio Report to discuss the significant unmet need in #gout, a disease that remains widely misunderstood and undertreated despite impacting millions of people worldwide. Listen to the episode here: https://t.co/FRgv3T73dx

[Crystalys_Tx @Crystalys_Tx]

We're advancing dotinurad, a next-generation, once-daily URAT1 inhibitor, to address significant unmet needs in #gout. It works by blocking uric acid reabsorption in the kidney, allowing more to be excreted and lowering serum uric acid levels. Learn more: https://t.co/nHcFr6GN5a

[Crystalys_Tx @Crystalys_Tx]

#MeetTheTeam – DeAnne Reid, is Executive Director, Operations & Business Development and co-founder of Crystalys. DeAnne’s decades of expertise helps drive us forward as we advance new treatments for patients living with #gout. For more on our team: https://t.co/GUmog6unn3

[Crystalys_Tx @Crystalys_Tx]

CEO, James Mackay, Ph.D., recently joined @ClinicalLeader1 for a conversation on the company’s strategy to advance dotinurad for the treatment of #gout directly into Phase 3 clinical trials, leveraging robust clinical and real-world data. Read here: https://t.co/x5q5R3lDbT

[Crystalys_Tx @Crystalys_Tx]

For most patients, #gout is caused by the body’s inability to eliminate uric acid. Current standard of care focuses on reducing uric acid production; our approach aims to address the root cause. Hear from our CEO James Mackay, Ph.D., on @ProgressPotent1: https://t.co/4MtiiFULZm

[Crystalys_Tx @Crystalys_Tx]

#MeetTheTeam - Ashwin Ram, MD, COO & co-founder of Crystalys. A physician-scientist and biotech entrepreneur, he brings deep experience in company building, clinical development, and operations as we advance new treatments for #gout. For more on our team: https://t.co/GUmog6unn3

[Crystalys_Tx @Crystalys_Tx]

Crystalys is looking forward to engaging with the investment community at two upcoming events later this April. We'll be sharing updates on our clinical progress and our efforts to advance new treatment options for patients living with #gout. For more: https://t.co/T0CSv9qw5R

[Crystalys_Tx @Crystalys_Tx]

Kidneys filter and remove uric acid from the body. Gout primarily occurs when the kidneys are unable to excrete enough uric acid resulting in it being deposited in the joints, causing painful flares and debilitating tophi. Learn about our therapy for gout: https://t.co/GknQLl2fP0

[Crystalys_Tx @Crystalys_Tx]

Crystalys is proud to sponsor the European Crystal Network Workshop 2026, taking place today and tomorrow in Paris. This meeting brings together leading experts focused on advancing the understanding and management of crystal-related diseases like #gout. https://t.co/Imv1a1l5Zj

[Crystalys_Tx @Crystalys_Tx]

Crystalys is on the ground in Miami for the Barclays 27th Annual Global Healthcare Conference. We’re meeting with investors and industry partners to discuss our advancing clinical programs to bring innovative treatment options to people living with #gout. https://t.co/GknQLl2fP0

[Crystalys_Tx @Crystalys_Tx]

Crystalys will be in Miami for the Leerink Partners 2026 Global Healthcare Conference next week, engaging with members of the biotech community to share updates on our mission to deliver new therapeutic options for patients living with #gout. For more:
https://t.co/T0CSv9qw5R

[Crystalys_Tx @Crystalys_Tx]

Crystalys is on the ground at the TD Cowen 46th Annual Health Care Conference in Boston. We are connecting with investors and industry leaders to discuss our clinical progress advancing new treatments for #gout. Learn about our therapy to treat gout: https://t.co/GknQLl2fP0

[Crystalys_Tx @Crystalys_Tx]

#MeetTheTeam – Nihar Bhakta, MD is CMO and co-founder of Crystalys, bringing expertise in clinical development, regulatory strategy, and patient advocacy to our leadership team. We’re proud to have Nihar’s clinical leadership guiding us as we advance new treatments for #gout.

[Crystalys_Tx @Crystalys_Tx]

We will be attending @Biocom's 16th Annual Global Life Science Partnering & Investor Conference in San Diego next week. We look forward to connecting with investors and industry leaders to discuss our work advancing new treatments for #gout. For more: https://t.co/uvTt1Xh9Ry

[Crystalys_Tx @Crystalys_Tx]

Former Chairman, President, and CEO of Horizon Therapeutics, Tim Walbert, has joined us as an Independent Director. Please join us in welcoming Tim as he supports our next stages of clinical development and readiness for commercialization of Dotinurad! https://t.co/KQkcEkFl75